4th Quarter - Report

SANOFI US SERVICES INC. for SANOFI US SERVICES INC

Firm
Client
Income
—
Expenses
$690,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Manufacturing MAN

Issues related to Pharmacy Benefit Managers (PBMs); issues related to Vaccines; issues related to Taxes; issues related to over the counter; and issues related to Insulin.

Foreign entity interest: Sanofi US Services Inc is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.

LobbyistCovered position, as disclosed
MORGAN BRADLEY-JONES —
KATIE OPPENHEIM —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; issues related to Type 1 Diabetes screening; issues related to intellectual property; issues related to Transplant; issues related HR 5339 and S. 3131 "Orphan Cures Act"; Rare Pediatric Priority Review Voucher Program related to HR 7834 "Creating Hope Reauthorization Act of 2024"; Orphan Drug Negotiation within HR5378 "Inflation Reduction Act"; issues related to drug price negotiations; issues related to COPD Research funding; Biologic/Small Molecule drug negotiation eligibility within HR7174 "EPIC Act"; CDC Type 1 Diabetes Awareness and Education with LHHS appropriations; issues related to S.4504 "SCREEN for Type 1 Diabetes"; issues related to HRSA - Type 1 Diabetes Screening in LHHS Appropriations; general issues related to Inflation Reduction Act; issues related to Routine Immunizations Rates; issues related to HR5376 "Inflation Reduction Act"; issues related to Rebate Pass Through; and issues related to S. 2916 "Prescription Information Modernization Act of 2023";

Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.

LobbyistCovered position, as disclosed
MORGAN BRADLEY-JONES —
CLAIRE WILLIS BRANDEWIE —
JENNIFER DALE —
KATIE OPPENHEIM —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 1542 (118th), S. 3131 (118th), H.R. 3656 (118th), S. 1339 (118th), S. 4504 (118th), H.R. 7834 (118th), H.R. 2880 (118th), H.R. 5378 (118th), H.R. 5376 (118th), H.R. 1503 (118th), S. 1375 (118th), H.R. 5339 (118th), S. 2916 (118th), H.R. 7174 (118th), H.R. 830 (118th)

Medicare/Medicaid MMM

Issues related to Medicare Negotiations; issues related to 340B; and issues related to Medicaid Drug Rebate Program rule.

Foreign entity interest: Sanofi US Services Inc is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.

LobbyistCovered position, as disclosed
CLAIRE WILLIS BRANDEWIE —
JENNIFER DALE —
KATIE OPPENHEIM —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Trade (domestic/foreign) TRD

Issues related to Importation; and issues related to Supply Chain.

Foreign entity interest: Sanofi US Services Inc is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.

LobbyistCovered position, as disclosed
MORGAN BRADLEY-JONES —
JENNIFER DALE —
KATIE OPPENHEIM —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

General issues related to Taxes; issues related to Vaccine Injury Compensation Program (VICP); issues related to HR 3656 (117th) Vaccine Access Improvement Act; issues related to supply chain; and issues related to TRIP Waivers.

Foreign entity interest: Sanofi US Services Inc is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.

LobbyistCovered position, as disclosed
MORGAN BRADLEY-JONES —
CLAIRE WILLIS BRANDEWIE —
JENNIFER DALE —
KATIE OPPENHEIM —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 3656 (118th)

Copyright/Patent/Trademark CPT

Issues related to Intellectual Property.

Foreign entity interest: Sanofi US Services Inc is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.

LobbyistCovered position, as disclosed
CLAIRE WILLIS BRANDEWIE —
JENNIFER DALE —
KATIE OPPENHEIM —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.